Formulary Search
Search Results : Bipolar disorder (adults) (Lithium citrate - Bipolar disorder (adults))
Show Icon and Status Keys
- Not Specified
To be initiated by a specialist.
This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the Blue information sheet and other resources that were in place prior to the launch of the joint formulary.
Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).
- Not Specified
To be initiated by a specialist.
This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the Blue information sheet and other resources that were in place prior to the launch of the joint formulary.
Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).
- Tablets
For the prevention of recurrence in bipolar disorder.
Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.
- Oro-dispersible tablets
For the prevention of recurrence in bipolar disorder.
Initiation by a SABP specilalist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.
Reserve orodispersible tablets for patients with swallowing difficulties or administration via a PEG tube.
- Immediate release tablets
For bipolar with mania / depression.
Initiation and stabilisation by a SABP specialist for a minimum of 3 months before any request for transfer of prescribing responsibility.
- Modified release tablets
For bipolar with mania / depression.
Modified release tablets are reserved for use when immediate release tablets are not suitable.
Modified release quetiapine MAY be continued in Primary Care (after a 3-month period of stabilisation by SABP) where the use of immediate release tablets would risk destabilising the patient.